Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.

LaBranche TP, Jesson MI, Radi ZA, Storer CE, Guzova JA, Bonar SL, Thompson JM, Happa FA, Stewart ZS, Zhan Y, Bollinger CS, Bansal PN, Wellen JW, Wilkie DP, Bailey SA, Symanowicz PT, Hegen M, Head RD, Kishore N, Mbalaviele G, Meyer DM.

Arthritis Rheum. 2012 Nov;64(11):3531-42. doi: 10.1002/art.34649.

2.

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ, Minnerly JC, Storer CE, LaBranche TP, Radi ZA, Dowty ME, Head RD, Meyer DM, Kishore N, O'Shea JJ.

J Immunol. 2011 Apr 1;186(7):4234-43. doi: 10.4049/jimmunol.1003668. Epub 2011 Mar 7.

3.

Characterization of the KRN cell transfer model of rheumatoid arthritis (KRN-CTM), a chronic yet synchronized version of the K/BxN mouse.

LaBranche TP, Hickman-Brecks CL, Meyer DM, Storer CE, Jesson MI, Shevlin KM, Happa FA, Barve RA, Weiss DJ, Minnerly JC, Racz JL, Allen PM.

Am J Pathol. 2010 Sep;177(3):1388-96. doi: 10.2353/ajpath.2010.100195. Epub 2010 Aug 9.

4.

Virus-plus-susceptibility gene interaction determines Crohn's disease gene Atg16L1 phenotypes in intestine.

Cadwell K, Patel KK, Maloney NS, Liu TC, Ng AC, Storer CE, Head RD, Xavier R, Stappenbeck TS, Virgin HW.

Cell. 2010 Jun 25;141(7):1135-45. doi: 10.1016/j.cell.2010.05.009.

5.

Reduced incidence and severity of experimental autoimmune arthritis in mice expressing catalytically inactive A disintegrin and metalloproteinase 8 (ADAM8).

Zack MD, Melton MA, Stock JL, Storer CE, Barve RA, Minnerly JC, Weiss DJ, Stejskal JA, Tortorella MD, Turk JR, Shevlin KM, Malfait AM.

Clin Exp Immunol. 2009 Nov;158(2):246-56. doi: 10.1111/j.1365-2249.2009.04009.x. Epub 2009 Aug 6.

Supplemental Content

Loading ...
Support Center